SPH.L

Sinclair Pharma Plc
AIM - Cancellation - Sinclair Pharma Plc
6th November 2018, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 3970G
AIM
06 November 2018
 

NOTICE

 

06/11/2018 7:00am

 

NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM - XLON

 

At the request of the Company the following securities have been cancelled from trading on AIM with effect from the time and date of this notice.

 

SINCLAIR PHARMA PLC

213800BNMD7JVMHW1772

ORDINARY SHARES OF 1P EACH, FULLY PAID

(3385674) (GB0033856740)

SINR PHAR/PAR VTG FPD 0.01

 

If you have any queries or require further information, please contact the company's nominated adviser on +44(0)20 7418 8900.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AMOMMMGMVKZGRZM ]]>
TwitterFacebookLinkedIn